跳至主要内容
临床试验/TCTR20220829001
TCTR20220829001已完成2 期

The randomized, double-blinded, controlled trial of Kaempferia parviflora versus Betahistine in treating chronic vertigenous patients

Argricultural Research Development Agency (Public Organization)0 个研究点目标入组 38 人开始时间: 2022年8月29日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
38

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 75 Years(—)
性别
All

入选标准

  • 1. Individual who suffered from chronic dizziness longer than 1 month with DHI-T score over 18
  • 2. Age 18-75 years
  • 3. Individual who are willing and able to comply with protocol until the end of project
  • 4. Able to read and write in Thai

排除标准

  • 1. Individual who had been diagnosed with Benign Paroxysmal Positional Vertigo or Vestibular Migraine or Height Vertigo or Orthostatic Hypotension or Mental or psychiatric problem
  • 2. Individual with abnormal proprioception including tremor and hemiplegia paraplegia
  • 3. Individual with cardiac arrythmia
  • 4. Individual who had been treated with and cannot withdraw EGb761 120mg/day or over or Betahistine 36 mg/day or over for longer than 72 hours
  • 5. Individual who currently consume other herbal medicines
  • 6. Individual who currently consume any kind of neurotic suppressor medications
  • 7. Individual with active otitis media or perforation of tympanic membrane
  • 8. Individual with abnormal liver and kidney function (GFR lower than 60)
  • 9. Individual who cannot sit or stand without assistant
  • 10. Individual with urine pregnancy test positive or in pregnancy condition

研究者

发起方
Argricultural Research Development Agency (Public Organization)

相似试验